SPIRIT II trial results boost Abbott's hope for EU DES (drug-eluting stent) debut next month
This article was originally published in Clinica
Executive Summary
Abbott looks set to become a key player in the lucrative drug-eluting stent (DES) arena, after its Xience V product outperformed Boston Scientific's market leading DES in a clinical trial.